Record Details

Efficacy and survival analysis of apatinib combined with capecitabine chemotherapy for second-line treatment of advanced esophageal cancer

NOPR - NISCAIR Online Periodicals Repository

View Archive Info
 
 
Field Value
 
Title Efficacy and survival analysis of apatinib combined with capecitabine chemotherapy for second-line treatment of advanced esophageal cancer
 
Creator Xu, Jinfa
Cai, Qing
Zhang, Xiufang
Zhang, Jianhua
 
Subject Advanced esophageal cancer
Apatinib
Capecitabine
Chemotherapy
Efficacy
Survival
 
Description 793-798
This study explore the efficacy, toxic and side effects and survival impact of apatinib combined with capecitabine
chemotherapy for the second-line treatment of advanced esophageal cancer. The clinical data of 76 patients with advanced
esophageal cancer treated from January 2015 to April 2020 have been retrospectively analyzed. They are divided into
experimental and control groups according to different treatment methods. The experimental group (n=29) underwent oral
apatinib targeted therapy (250 mg/once/d) combined with oral capecitabine chemotherapy (1000 mg/m2 according to the
body surface area on D1-14). Maintenance therapy with apatinib has been conducted after 4-6 cycles. The control group
(n=47) received the second-line chemotherapy. After more than 2 cycles of chemotherapy, complete response is achieved in
0 cases, partial response in 19 cases, stable disease in 6 cases, and progressive disease in 3 cases. Overall response rate
(ORR) is found to be 67.86% and the disease control rate is 89.28%. The median progression-free survival (mPFS) and the
median overall survival (mOS) are 6.7 months and 8.9 months, respectively. Karnofsky Performance Status score of
2 points, liver metastasis, elevation of tumor marker squamous cell carcinoma and unsatisfactory efficacy are independent
prognostic factors. In control group, ORR was 34.04%, and mPFS and mOS are 3.9 months and 7.4 months, respectively.
No severe drug-related toxic and side effects have been observed, except for 1 patient who voluntarily discontinued
treatment due to grade III hypertension. Apatinib combined with capecitabine chemotherapy shows good overall efficacy
with satisfactory safety and tolerance for the second-line treatment of advanced esophageal cancer.
 
Date 2022-11-18T10:00:11Z
2022-11-18T10:00:11Z
2022-11
 
Type Article
 
Identifier 0975-0991 (Online); 0971-457X (Print)
http://nopr.niscpr.res.in/handle/123456789/60834
https://doi.org/10.56042/ijct.v29i6.67385
 
Language en
 
Publisher NIScPR-CSIR, India
 
Source IJCT Vol.29(6) [November 2022]